677
Participants
Start Date
February 11, 2016
Primary Completion Date
March 7, 2019
Study Completion Date
March 7, 2019
Active group with MEMS
Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
Active group without MEMS
Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
Control group with MEMS
Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
Control group without MEMS
Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
Research Site, Berlin
Research Site, Tegel
Research Site, Bernau
Research Site, Rostock
Research Site, Hamburg
Research Site, Lübeck
Research Site, Kiel
Research Site, Oldenburg
Research Site, Bad Bevensen
Research Site, Kassel
Research Site, Kassel
Research Site, Rotenburg (Wümme)
Research Site, Barby
Research Site, Düsseldorf
Research Site, Erkrath
Research Site, Mönchengladbach
Research Site, Wuppertal
Research Site, Essen
Research Site, Gelsenkirchen
Research Site, Kleve
Research Site, Münster
Research Site, Mainz
Research Site, Siegen
Research Site, Frankfurt
Research Site, Heidelberg
Research Site, Bad Krozingen
Research Site, Regensburg
Research Site, Coburg
Research Site, Bad Berka
Research Site, Berlin
Research Site, Chemnitz
Lead Sponsor
AstraZeneca
INDUSTRY